PVI
IMDX

Pura Vida Investments’s Insight Molecular Diagnostics IMDX Stock Holding History

Pura Vida Investments’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.86M Sell
484,845
-462,289
-49% -$2.28M 7.73% 4
2026
Q1 		$3.11M Hold
947,134
– – 20.88% 1
2025
Q4 		$7.1M Hold
947,134
– – 26.55% 2
2025
Q3 		$3.14M Buy
947,134
+928,434
+4,965% +$2.62M 19.16% 2
2025
Q2 		$2.86M Sell
18,700
-928,434
-98% -$2.81M 17.2% 2
2025
Q1 		$2.9M Buy
947,134
+292,683
+45% +$791K 21.17% 2
2024
Q4 		$1.56M Buy
654,451
+159,106
+32% +$432K 4.93% 10
2024
Q3 		$1.41M Hold
495,345
– – 0.92% 30
2024
Q2 		$1.46M Sell
495,345
-28,583
-5% -$78.6K 0.92% 32
2024
Q1 		$1.54M Sell
523,928
-63,002
-11% -$195K 0.26% 38
2023
Q4 		$1.47M Sell
586,930
-71,191
-11% -$219K 0.22% 39
2023
Q3 		$2.05M Sell
658,121
-23,130
-3% -$86.1K 0.39% 59
2023
Q2 		$3.13M Sell
681,251
-27,057
-4% -$136K 0.42% 51
2023
Q1 		$5.02M Sell
708,308
-194,506
-22% -$1.44M 0.51% 48
2022
Q4 		$5.79M Hold
902,814
– – 0.3% 81
2022
Q3 		$13.2M Hold
902,814
– – 0.76% 35
2022
Q2 		$16.2M Buy
902,814
+291,616
+48% +$6.63M 0.94% 25
2022
Q1 		$18.2M Hold
611,198
– – 0.59% 40
2021
Q4 		$26.5M Hold
611,198
– – 0.96% 24
2021
Q3 		$43.5M Hold
611,198
– – 1.32% 12
2021
Q2 		$70.2M Hold
611,198
– – 2.18% 6
2021
Q1 		$63.4M Buy
611,198
+297,057
+95% +$28.2M 1.81% 9
2020
Q4 		$15M Buy
314,141
+13,014
+4% +$477K 0.55% 46
2020
Q3 		$8.37M Buy
301,127
+1,941
+0.6% +$55.7K 0.43% 47
2020
Q2 		$11.4M Buy
299,186
+20,272
+7% +$1.05M 1.1% 23
2020
Q1 		$13.7M Sell
278,914
-5,915
-2% -$290K 1.62% 18
2019
Q4 		$12.8M Buy
+284,829
New +$10.3M 1.13% 30

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pura Vida Investments's IMDX Position: Q2 2026 in Review

Pura Vida Investments reduced its Insight Molecular Diagnostics (IMDX) stake by 49% in Q2 2026, selling an estimated $2.28M and leaving 484,845 shares worth $2.86M. The position accounts for 7.73% of the portfolio, ranked #4.

Pura Vida Investments first reported a position in IMDX in Q4 2019 and has held it in 27 quarters since. The position peaked at $70.2M in Q2 2021. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • Pura Vida Investments held 484,845 shares of Insight Molecular Diagnostics worth $2.86M as of Q2 2026.
  • Pura Vida Investments sold 462,289 Insight Molecular Diagnostics shares in Q2 2026, an estimated $2.28M.
  • Insight Molecular Diagnostics made up 7.73% of Pura Vida Investments's portfolio in Q2 2026, its #4 holding.
  • Pura Vida Investments first reported a position in Insight Molecular Diagnostics in Q4 2019 and has held it in 27 quarters since.
  • Pura Vida Investments's Insight Molecular Diagnostics position peaked at $70.2M in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Pura Vida Investments's 13F filing for Q2 2026, filed 13 Aug 2026.